Literature DB >> 17289130

Behavioral sensitization produced by a single administration of apomorphine: implications for the role of Pavlovian conditioning in the mediation of context-specific sensitization.

Enrrico Bloise1, Robert J Carey, Marinete Pinheiro Carrera.   

Abstract

The present study examined the minimal number of exposures to the D1/D2 agonist apomorphine capable of producing behavioral sensitization. Rats received one (experiment 1) or two administrations on two successive days (experiment 2) of apomorphine (0.5 and 2.0 mg/kg) paired or unpaired to an open-field environment. After 2 days of drug withdrawal, the rats received a challenge injection with the same dose of apomorphine (sensitization test) and locomotion, rearing and sniffing were measured. The results of the first experiment showed that locomotor sensitization occurred after a single acute exposure to apomorphine and that 0.5 and 2.0 mg/kg treatments were equally effective. This sensitization effect was context-specific and was limited to locomotion. The second experiment revealed a differential dose effect on the sensitization test. Two treatments with 2.0 mg/kg potentiated locomotor sensitization as compared with a single treatment but two treatments with 0.5 mg/kg did not increase the sensitization effect more than the single 0.5 mg/kg treatment. This result indicates an interaction between drug dose and frequency of drug treatment for the induction of apomorphine locomotor sensitization. In that the sensitization effects are considered to be a core contributor to psychostimulant addiction, the present findings are of importance to understanding addiction because they indicate that sensitization processes can be initiated with a single drug experience and amplified with exposure to higher drug dosage levels.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17289130     DOI: 10.1016/j.pbb.2007.01.002

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  6 in total

1.  Memory re-consolidation and drug conditioning: an apomorphine conditioned locomotor stimulant response can be enhanced or reversed by a single high versus low apomorphine post-trial treatment.

Authors:  Marinete Pinheiro Carrera; Robert J Carey; Flávia Regina Cruz Dias; Liana Wermelinger de Mattos
Journal:  Psychopharmacology (Berl)       Date:  2011-09-16       Impact factor: 4.530

2.  Residual dopamine receptor desensitization following either high- or low-dose sub-chronic prior exposure to the atypical anti-psychotic drug olanzapine.

Authors:  Flávia Regina Cruz Dias; Liana Wermelinger de Matos; Maria de Fátima Dos Santos Sampaio; Robert J Carey; Marinete Pinheiro Carrera
Journal:  Psychopharmacology (Berl)       Date:  2012-07-24       Impact factor: 4.530

3.  Apomorphine-induced context-specific behavioural sensitization is prevented by the D1 antagonist SCH-23390 but potentiated and uncoupled from contextual cues by the D2 antagonist sulpiride.

Authors:  Flávia Regina Cruz Dias; Robert J Carey; Marinete Pinheiro Carrera
Journal:  Psychopharmacology (Berl)       Date:  2010-02-23       Impact factor: 4.530

4.  Maternal separation fails to render animals more susceptible to methamphetamine-induced conditioned place preference.

Authors:  Jacqueline Faure; Dan J Stein; William Daniels
Journal:  Metab Brain Dis       Date:  2009-10-10       Impact factor: 3.584

5.  The involvement of type IV phosphodiesterases in cocaine-induced sensitization and subsequent pERK expression in the mouse nucleus accumbens.

Authors:  Amy C Janes; Kathleen M Kantak; James A Cherry
Journal:  Psychopharmacology (Berl)       Date:  2009-07-09       Impact factor: 4.530

6.  Galphimia glauca and Natural Galphimines Block Schizophrenia-Like Symptoms Induced with Apomorphine and MK-801 in Mice.

Authors:  Mayra Alejandra Santillán-Urquiza; Maribel Herrera-Ruiz; Alejandro Zamilpa; Enrique Jiménez-Ferrer; Rubén Román-Ramos; Elian Yuritzi Alegría-Herrera; Jaime Tortoriello
Journal:  Evid Based Complement Alternat Med       Date:  2019-07-21       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.